Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
US-2024252425-A1 · Aug 1, 2024 · US
Methods for treating intrapulmonary infections
US9724353B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9724353-B2 |
| Application number | US-201414512608-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 13, 2014 |
| Priority date | Sep 9, 2011 |
| Publication date | Aug 8, 2017 |
| Grant date | Aug 8, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating an infection selected from the group consisting of: nosocomial pneumonia, ventilator acquired pneumonia and hospital acquired pneumonia, the method comprising repeatedly intravenously administering 2.0 g of ceftolozane and 1.0 g of tazobactam to a subject in need thereof about once every 8 hours. 2. The method of claim 1 , wherein the method comprises administering the ceftolozane as a 60-minute infusion. 3. The method of claim 1 , wherein the ceftolozane is a hydrogen sulfate salt. 4. The method of claim 1 , wherein the ceftolozane and tazobactam are administered as a single pharmaceutical composition. 5. The method of claim 4 , wherein the method comprises administering the pharmaceutical composition as a 60-minute infusion. 6. The method of claim 1 , wherein the pneumonia is nosocomial pneumonia. 7. The method of claim 1 , wherein the pneumonia is ventilator acquired pneumonia. 8. The method of claim 1 , wherein the pneumonia is hospital acquired pneumonia. 9. The method of claim 1 , wherein the ceftolozane is administered in its free base form. 10. The method of claim 1 , wherein the ceftolozane is administered in its salt form. 11. The method of claim 6 , wherein the ceftolozane is administered in its free base form. 12. The method of claim 6 , wherein the ceftolozane is administered in its salt form. 13. The method of claim 1 , wherein the infection comprises one or more pathogens selected from the group consisting of: Pseudomonas aeruginosa, E. coli and K. pneumoniae.
Assignees
Inventors
Classifications
Antibacterial agents · CPC title
- A61K31/546Primary
containing further heterocyclic rings, e.g. cephalothin · CPC title
Pulmonary tract; Aromatherapy · CPC title
containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9724353B2 cover?
- This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.
- Who is the assignee on this patent?
- Calixa Therapeutics Inc, Merck Sharp & Dohme
- What technology area does this patent fall under?
- Primary CPC classification A61K31/546. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).